Role of functional single nucleotide polymorphisms of MMP1, MMP2, and MMP9 in open angle glaucomas.
OBJECTIVE
Matrix metalloproteinases (MMPs) play an essential role in the turnover of the extracellular matrix and cellular behavior. MMP1, MMP2, and MMP9 have previously been implicated in the pathogenesis of primary open angle glaucoma (POAG) and open angle glaucoma secondary to exfoliation syndrome (XFG), respectively. Functional gene polymorphisms of these MMPs such as MMP1 -1607 1G/2G (rs1799750), MMP2 -1306 C/T (rs243865), MMP2 -1575 G/A (rs243866), and MMP9 Q279R (rs17576) are thus plausible candidates as risk factors for open angle glaucomas. The purpose of the present study was to investigate hypothesized associations between these polymorphisms and the presence of POAG and XFG in a Caucasian population.


METHODS
The present case-control study included 322 patients with POAG, 202 patients with XFG, and 248 control subjects. Genotyping of polymorphisms was done using polymerase chain reaction.


RESULTS
No significant differences in either genotype distributions or allelic frequencies of MMP1 -1607 1G/2G, MMP2 -1306 C/T, MMP2 -1575 G/A, and MMP9 Q279R were found between patients with POAG and control subjects and patients with XFG and control subjects, respectively (p>0.05). The presence of POAG or XFG was not predicted by any of the investigated polymorphisms.


CONCLUSIONS
Our data suggest that the MMP1 -1607 1G/2G, MMP2 -1306 C/T, MMP2 -1575 G/A, and MMP9 Q279R polymorphisms themselves are unlikely major risk factors among Caucasian patients with either POAG or XFG.
Mossböck
Georg
G
Department of Ophthalmology, Medical University of Graz, Graz, Austria. g.mossboeck@medunigraz.at
Weger
Martin
M
Faschinger
Christoph
C
Zimmermann
Christine
C
Schmut
Otto
O
Renner
Wilfried
W
El-Shabrawi
Yosuf
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D017889:Exfoliation Syndrome / Q000201:enzymology / Q000235:genetics; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D005902:Glaucoma, Open-Angle / Q000201:enzymology* / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000235:genetics; D020778:Matrix Metalloproteinase 2 / Q000235:genetics; D020780:Matrix Metalloproteinase 9 / Q000235:genetics; D020782:Matrix Metalloproteinases / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*
D020782:Matrix Metalloproteinases; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; C522360:MMP1 protein, human; D020781:Matrix Metalloproteinase 1
N Engl J Med. 2009 Mar 12;360(11):1113-24
19279343
Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1117-25
12601038
Annu Rev Cell Dev Biol. 2001;17:463-516
11687497
Mol Vis. 2010 Feb 06;16:167-77
20142848
Exp Eye Res. 1998 Aug;67(2):179-91
9733584
Mol Vis. 2008 May 09;14:857-61
18483563
BMC Med Genet. 2008 Feb 06;9:5
18254956
Science. 1997 Jan 31;275(5300):668-70
9005853
Science. 2007 Sep 7;317(5843):1397-400
17690259
J Glaucoma. 2008 Jun-Jul;17(4):257-8
18552608
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2649-58
9856774
Prog Retin Eye Res. 2002 Jul;21(4):359-93
12150988
BMC Med Genet. 2006 Apr 27;7:40
16643654
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2648-53
12147598
J Biol Chem. 2002 Dec 6;277(49):47461-8
12354772
J Biol Chem. 1989 Jan 5;264(1):393-401
2462561
Mol Vis. 2009 Dec 25;15:2890-5
20038976
Hum Mol Genet. 2008 Mar 1;17(5):710-6
18037624
Mol Vis. 2008 Feb 09;14:318-22
18334947
J Glaucoma. 2005 Feb;14(1):64-9
15650607
Curr Opin Ophthalmol. 2003 Dec;14(6):353-6
14615639
J Biol Chem. 2003 Jun 6;278(23):20490-9
12657623
J Biol Chem. 2001 Mar 9;276(10):7549-58
11114309
Mol Vis. 2009 Jul 24;15:1412-7
19633731
Mol Vis. 2008 Jan 29;14:146-9
18334928
J Biol Chem. 1991 Jul 25;266(21):14064-71
1649834
Am J Ophthalmol. 2008 Mar;145(3):582-585
18201684
Mol Vis. 2008 Mar 17;14:533-41
18385788
Bull World Health Organ. 2004 Nov;82(11):844-51
15640920
Mol Vis. 2006 Oct 26;12:1223-32
17110919
Exp Eye Res. 2009 Apr;88(4):769-75
19114037
Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86
7706025
Clin Cancer Res. 2005 Aug 1;11(15):5433-9
16061858
Am J Ophthalmol. 2007 Dec;144(6):974-975
18036875
J Cell Physiol. 2007 Apr;211(1):19-26
17167774
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5174-81
14638714
Brain Res. 2003 Mar 28;967(1-2):132-43
12650974
Exp Eye Res. 2008 Apr;86(4):543-61
18313051
Am J Hum Genet. 2008 May;82(5):1122-9
18455130
Arch Ophthalmol. 2002 Sep;120(9):1189-97
12215093
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):175-82
15623771
Cancer Res. 1998 Dec 1;58(23):5321-5
9850057
Cell Cycle. 2008 Feb 15;7(4):521-4
18287813
Glia. 2001 Mar 1;33(3):205-16
11241738